Mostrar el registro sencillo del ítem
dc.contributor.author | Bustos Palomino, Javier Arturo | |
dc.contributor.author | Gonzales, Isidro | |
dc.contributor.author | Saavedra Pastor, Herbert | |
dc.contributor.author | Handali, Sukwan | |
dc.contributor.author | García Lescano, Héctor Hugo | |
dc.contributor.author | Cysticercosis Working Group in Peru | |
dc.date.accessioned | 2021-10-04T23:00:59Z | |
dc.date.available | 2021-10-04T23:00:59Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/9864 | |
dc.description.abstract | Neurocysticercosis is endemic in most of the world and in endemic areas it accounts for approximately 30% of cases of epilepsy. Appropriate diagnosis and management of neurocysticercosis requires understanding the diverse presentations of the disease since these will vary in regards to clinical manifestation, sensitivity of diagnostic tests, and most importantly, therapeutic approach. This review attempts to familiarize tropical neurology practitioners with the diverse types of neurocysticercosis and the more appropriate management approaches for each | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Journal of the Neurological Sciences | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | albendazole | en_US |
dc.subject | antiinflammatory agent | en_US |
dc.subject | antiparasitic agent | en_US |
dc.subject | Article | en_US |
dc.subject | clinical feature | en_US |
dc.subject | cognitive defect | en_US |
dc.subject | computer assisted tomography | en_US |
dc.subject | cysticercosis | en_US |
dc.subject | Cysticercosis | en_US |
dc.subject | disease classification | en_US |
dc.subject | disease course | en_US |
dc.subject | disease severity assessment | en_US |
dc.subject | epilepsy | en_US |
dc.subject | Epilepsy | en_US |
dc.subject | headache | en_US |
dc.subject | human | en_US |
dc.subject | infection control | en_US |
dc.subject | intracranial hypertension | en_US |
dc.subject | mental disease | en_US |
dc.subject | neurocysticercosis | en_US |
dc.subject | Neurocysticercosis | en_US |
dc.subject | neuroimaging | en_US |
dc.subject | neurologic disease | en_US |
dc.subject | neurologist | en_US |
dc.subject | nonhuman | en_US |
dc.subject | nuclear magnetic resonance imaging | en_US |
dc.subject | parasite clearance | en_US |
dc.subject | praziquantel | en_US |
dc.subject | prognosis | en_US |
dc.subject | Research Diagnostic Criteria | en_US |
dc.subject | retina | en_US |
dc.subject | seizure | en_US |
dc.subject | serology | en_US |
dc.subject | spinal cord | en_US |
dc.subject | subarachnoid space | en_US |
dc.subject | Taenia solium | en_US |
dc.subject | treatment planning | en_US |
dc.subject | Tropical neurology | en_US |
dc.title | Neurocysticercosis. A frequent cause of seizures, epilepsy, and other neurological morbidity in most of the world | en_US |
dc.type | info:eu-repo/semantics/review | |
dc.identifier.doi | https://doi.org/10.1016/j.jns.2021.117527 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.25 | |
dc.relation.issn | 1878-5883 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |